Dr. Joel Emanuel Gallant

(Reading, Writing, Speaking)

• Gallant J (2008) 100 Questions and Answers about HIV and AIDS, Sudbury, MA, Jones & Bartlett Publishers, In Press
• Riddell J 4th, Kaul DR, Karakousis PC, Gallant JE, Mitty J, Kazanjian PH (2007) Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes, J Transl Med, 5 (1), 50
• Atta M, Gallant JE, Rahman H, Nagajothi N, Racusen LC, Scheel PJ, Fine DM (2007) Antiretroviral therapy in the treatment of HIV-associated nephropathy, Nephrol Dial Transplant, In Press
• Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J Jr, Moore RD, Gange SJ, Silicinao RF (2007) Stability of the latent reservoir for HIV-1 in patients receiving valproic acid, J Infect Dis, 195, 833-6
• Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J, Pierone G, Saag M, van Baelen B, Lefebvre E (2007) Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced patients, AIDS, 21, F11-18
• Sax PE, Gallant JE, Klotman PE (2007) Renal safety of tenofovir disoproxil fumarate, AIDS Reader, 17, 90-104
• Gallant JE (2007) Should antiretroviral therapy be started earlier?, Current HIV/AIDS Reports, 4, 53-9
• Hoffman CJ, Gallant JE (2007) When and how to use tipranavir and darunavir, AIDS Reader, 17, 194-8
• Gallant JE (2007) Approach to the treatment-experienced patient, Infect Dis Clin North Amer, 12, 85-102
• Gallant JE (2007) Drug resistance after failure of initial antiretroviral therapy in resource-limited countries [editorial], Clin Infect Dis, 44, 453-5
• Bartlett, JG, Gallant JE (2007) 2007 Medical Management of HIV Infection, Baltimore, : Johns Hopkins Medicine Health Publishing Business Group
• Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK (2006) Tenofovir, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV, N Engl J Med, 354, 251-60
• Mbulaiteye SM, Atkinson JO, Whitby D, Wohl DA, Gallant JE, Royal S, Goedert JJ, Rabkin CS (2006) Risk factors for human herpesvirus 8 seropositivity in the AIDS Cancer Cohort Study, J Clin Virol, 35, 442-9
• Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J, Gallant JE, Carson K, Siliciano RF, Flexner C (2006) Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring, Clin Infect Dis, 42, 1189-96
• Sabundayo BP, McArthur JH, Langan SJ, Gallant JE, Margolick JB (2006) High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection, Pharmacotherapy, 26, 674-81
• Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J Jr, Quinn TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, Siliciano RF (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells, J Virol, 80, 6441-57
• Estrella M, Fine DM, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, Atta MG (2006) HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients, Clin Infect Dis, 43, 377-80
• Li X, Chu H, Gallant JE, Hoover DR, Mack WJ, Chmiel JS, Muñoz A (2006) Bimodal virologic response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring, J Epidemiol Community Health, 60, 811-8
• Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes: a 96-week analysis, J Acquir Immune Defic Syndr, 43, 535-40
• Pham PA, Gallant JE (2006) Tenofovir disoproxil fumarate for the treatment of HIV infection, Expert Opin Drug Metab Toxicol, 2, 459-69
• Gallant JE (2006) The M184V mutation: what it does, how to prevent it, and what to do with it when it's there, AIDS Reader, 16, 556-8
• Gallant JE (2006) Treating the experienced patient--when and how to use new agents [editorial], AIDS Reader, 16, 274-5
• Gallant JE (2006) predictors of response--updating the traditional list [editorial], AIDS Reader, 16, 432-3
• Gallant JE, Lim ML, Shaefer MS (2006) Tenofovir, abacavir and lamivudine: Reply to Carr [letter], J Infect Dis, 193, 1742-3
• Gallant JE, DeJesus E, Cheng AK (2006) Tenofovir DF and emtricitabine vs. Zidovudine and lamivudine: Reply [letter], N Engl J Med, 354, 2507-8
• Gallant JE (2005) Antiretroviral drug resistance and resistance testing, Top HIV Med, 13, 138-42
• Gallant JE, Shafer R (Sep 2005) Antiretroviral rounds. Virologic failure: true or false?, Aids Clinical Care, 17 (9), 84-5
• Gallant JE (Jun 2005) Approach to the treatment-experienced patient, Curr Hiv/aids Rep, 2 (2), 83-9
• Gallant JE, Parish MA, Keruly JC, Moore RD (Apr 2005) Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment, Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 40 (8), 1194-8
• Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G, Study 903 Team (Apr 2005) Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study, Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 20 (4), 743-6
• Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF (Feb 2005) Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART, Jama : the Journal of the American Medical Association, 293 (7), 817-29
• Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger D, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS (2005) . Early virologic non-response to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral naïve subjects, Journal of Infectious Diseases, 192, 1921-30
• Nawar E, Mbulaiteye SM, Gallant JE, Wohl DA, Ardini M, Hendershot T, Goedert JJ, Rabkin CS (2005) Risk factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS, Int J Cancer, 115, 296-300
• Nettles RE, Kieffer TL, Cofrancesco J, Gallant JE, Quinn T, Jackson B, Flexner C, Carson KA, Wu AW, Siliciano RF (2005) Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAART, HIV Clin Trials, 6, 262-71
• Gallant JE (2005) Approach to the treatment-experienced patient, Current HIV/AIDS Reports, 2, 83-9
• Doherty MC, Gallant JE (2005) Current issues in initiation of antiretroviral therapy, Infect Med, 22, 599-615
• Gallant JE (2005) Learning from HIV and AIDS [book review], J Epidemiol Community Health, 59, 609-11
• Bartlett JG, Gallant JE (2005) 2005-2006 Medical Management of HIV Infection, Baltimore, Johns Hopkins Medicine Health Publishing Business Group
• Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, Munoz A (Dec 2004) Prognostic Value of Plasma HIV RNA Among Highly Active Antiretroviral Therapy Users, Aids (london, England), 18 (18), 2419-23
• Gallant JE (Dec 2004) Editorial Comment: Strategies for Success--a Return to "hit Early"?, The Aids Reader, 14 (12), 662-3
• Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J Jr, Moore RD, Gallant JE, Persaud D, Siliciano RF (Oct 2004) Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy, Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 39 (7), 1030-7
• Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE, HIV Medicine Association of the Infectious Diseases Society of America (Sep 2004) Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association Of the Infectious Diseases Society of America, Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 39 (5), 609-29
• Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study Group (Jul 2004) Efficacy and Safety of Tenofovir DF Vs Stavudine in Combination Therapy In Antiretroviral-naive Patients: a 3-year Randomized Trial, Jama : the Journal of the American Medical Association, 292 (2), 191-201
• Lucas GM, Gallant JE, Moore RD (Jul 2004) Relationship Between Drug Resistance and HIV-1 Disease Progression Or Death in Patients Undergoing Resistance Testing, Aids (london, England), 18 (11), 1539-48
• Gallant JE (Jul 2004) HIV Counseling, Testing, and Referral, American Family Physician, 70 (2), 295-302
• Gallant JE (Jun 2004) Editorial Comment: Thoughts on the Once-daily-dosing Bandwagon, The Aids Reader, 14 (6), 330-1
• Sethi AK, Celentano DD, Gange SJ, Gallant JE, Vlahov D, Farzadegan H (Apr 2004) High-risk behavior and potential transmission of drug-resistant HIV among injection drug users, Journal of Acquired Immune Deficiency Syndromes (1999), 35 (5), 503-10
• Bartlett JG, Gallant JE (2004) 2004 Medical Management of HIV Infection, Baltimore, Johns Hopkins Medicine Health Publishing Business Group
• Gallant JE (2004) Human immunodeficiency virus infection, Current Therapy in Allergy, Immunology, and Rheumatology, Philadelphia, Mosby (bookchapter)
• Gallant JE (Oct-Dec 2004) Protease-inhibitor boosting in the treatment-experienced patient, Aids Reviews, 6 (4), 226-33
• Tarwater PM, Parish M, Gallant JE (Dec 2003) Prolonged Treatment Interruption After Immunologic Response to Highly Active Antiretroviral Therapy, Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 37 (11), 1541-8
• Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS, Richman DD (Dec 2003) Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance, Antiviral Therapy, 8 (6), 489-506
• Gallant JE, Deresinski S (Oct 2003) Tenofovir Disoproxil Fumarate, Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 37 (7), 944-50
• Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE (Oct 2003) Association Between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance, Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 37 (8), 1112-8
• Gallant JE, Pham PA (Oct 2003) Tenofovir Disoproxil Fumarate (Viread) for the Treatment of HIV Infection, Expert Review of Anti-infective Therapy, 1 (3), 415-22
• Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM (Mar 2003) A Phase II Clinical Study of the Long-term Safety and Antiviral Activity of Enfuvirtide-based Antiretroviral Therapy, Aids (london, England), 17 (5), 691-8
• Jackson JB, Barnett S, Piwowar-Manning E, Apuzzo L, Raines C, Hendrix C, Hamzeh F, Gallant J (Mar 2003) A Phase I/II Study of Nevirapine for Pre-exposure Prophylaxis of HIV-1 Transmission in Uninfected Subjects At High Risk, Aids (london, England), 17 (4), 547-53
• Kuritzkes DR, Boyle BA, Gallant JE, Squires KE, Zolopa A (Mar 2003) Current Management Challenges in HIV: Antiretroviral Resistance, The Aids Reader, 13 (3), 133-5, 138-42
• Gallant J (2003) Tipranavir, Drugs, 63 (15), 1619-20
• Bartlett JG, Gallant JE (2003) 2003 Medical Management of HIV Infection, Baltimore, Johns Hopkins University Division of Infectious Diseases
• Zolopa AR, Gallant J (2003) Treatment-experienced patients, HIV Clinical Manual, Pittsburgh, ESun Technologies, LLC, 29-34 pages (bookchapter)
• Gallant JE (Dec 2002) Initial Therapy of HIV Infection, Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 25 (3), 317-33
• Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ, Sun E (Dec 2002) Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting Of Indinavir-based Therapy in Human Immunodeficiency Virus-infected Patients With Ongoing Viremia, Antimicrobial Agents and Chemotherapy, 46 (12), 3907-16
• Gallant JE (Dec 2002) Initial therapy of HIV infection, Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 25 (3), 317-33
• Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A (Jul 2002) The Safety, Plasma Pharmacokinetics, and Antiviral Activity Of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of Gp41-mediated Virus Fusion, in HIV-infected Adults, Aids Research and Human Retroviruses, 18 (10), 685-93
• Blankson JN, Gallant JE, Quinn TC, Bartlett JG, Siliciano RF (Jul 2002) Loss of HIV-1-specific Immunity During Treatment Interruption in 2 Chronically Infected Patients, Jama : the Journal of the American Medical Association, 288 (2), 162-4
• Zolopa AR, Gallant J (2002) Treatment-experienced patients, Antimicrobial Therapy and Vaccines, Vol 1: Microbes, New York, Apple Trees Productions, LLC, 1274-8 pages (bookchapter)
• Barreiro P, Garcia-Benayas T, Soriano V, Gallant J (Oct-Dec 2002) Simplification of Antiretroviral Treatment--how to Sustain Success, Reduce Toxicity and Ensure Adherence Avoiding PI Use, Aids Reviews, 4 (4), 233-41
• Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, Gallant JE (Sep 2001) Time to Initiating Highly Active Antiretroviral Therapy Among HIV-infected Injection Drug Users, Aids (london, England), 15 (13), 1707-15
• Blankson JN, Gallant JE, Siliciano RF (Feb 2001) Proliferative Responses to Human Immunodeficiency Virus Type 1 (HIV-1) Antigens in HIV-1-infected Patients With Immune Reconstitution, The Journal of Infectious Diseases, 183 (4), 657-61
• Bartlett JG, Gallant JE (2001) 2001-2002 Medical Management of HIV Infection, Baltimore, Johns Hopkins University Division of Infectious Diseases
• Raines CP, Flexner C, Sun E, Heath-Chiozzi M, Lewis RH, Fields C, Deetz C, Apuzzo L, Eshleman SH, Jackson JB, Gallant JE (2000) Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks, Journal of Acquired Immune Deficiency Syndromes : Jaids, 25 (4), 322-8
• Haas DW, Arathoon E, Thompson MA, de Jesus Pedro R, Gallant JE, Uip DE, Currier J, Noriega LM, Lewi DS, Uribe P, Benetucci L, Cahn P, Paar D, White AC, Collier AC, Ramirez-Ronda CH, Harvey C, Chung MO, Mehrotra D, Chodakewitz J, Nguyen BY (2000) Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine, Aids, 14 (13), 1973-8
• Gallant JE (March 2000) Strategies for long-term success in the treatment of HIV infection [clinical conference], Jama, 283 (10), 1329-34
• Bartlett JG, Gallant JE (2000) 2000-2001 Medical Management of HIV Infection, Baltimore, Johns Hopkins University Division of Infectious Diseases
• Chaisson RE, Sterling TR, Gallant JE (2000) General clinical manifestations of human immunodeficiency virus infection (including oral, cutaneous, ocular, and cardiac diseases), Principles and Practice of Infectious Diseases, Philadelphia, Churchill Livingstone, 1398-1415 pages (bookchapter)
• Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE, Perfect JR (December 1999) Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy, Aids Research and Human Retroviruses, 15 (18), 1619-23
• Hall CS, Raines CP, Barnett SH, Moore RD, Gallant JE (9 Jul 1999) Efficacy of Salvage Therapy Containing Ritonavir and Saquinavir After Failure of Single Protease Inhibitor-containing Regimens, AIDS, 13 (10), 1207-12
• Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF (May 1999) Latent Infection of CD4+ T Cells Provides a Mechanism for Lifelong Persistence of HIV-1, Even in Patients on Effective Combination Therapy, Nat Med, 5 (5), 512-7
• Gallant JE, Chaisson RE, Keruly JC, Moore RD (4 Feb 1999) Stavudine in Zidovudine \(ZDV\)-experienced Compared With ZDV-naive Patients, AIDS, 13 (2), 225-9
• Gallant J E, Chaisson R E, Moore R D (1998) The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications, CHEST, 114 (5), 1258-63
• Chaisson R E, Gallant J E, Keruly J C, Moore R D (1 1998) Impact of opportunistic disease on survival in patients with HIV infection, AIDS, 12 (1), 29-33
• Erbelding EJ, Gallant JE, Chaisson RE (1998) Pulmonary complications in HIV infection, A Clinical Guide to AIDS and HIV, Philadelphia, Lippincott-Raven Publishers, 373-8 pages (bookchapter)
• Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF (14 Nov 1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science, 278 (5341), 1295-300
• Pons V, Greenspan D, Lozada-Nur F, McPhail L, Gallant JE, Tunkel A, Johnson CC, McCarty J, Panzer H, Levenstein M, Barranco A, Green S (June 1997) Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions, Clinical Infectious Diseases, 24 (6), 1204-7
• Maenza J R, Merz W G, Romagnoli M J, Keruly J C, Moore R D, Gallant J E (1997) Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology, CLINICAL INFECTIOUS DISEASES, 24 (1), 28-34
• Gallant JE (1997) Nonhospital management of human immunodeficiency virus infection, Textbook of Internal Medicine, Philadelphia, Lippincott-Raven Publishers, 1998-90 pages (bookchapter)
• Cheever L W, Chaisson R E, Gallant J E (1996) Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus, WESTERN JOURNAL OF MEDICINE, 165 (1-2), 67-73
• Chaisson R E, Keruly J C, McAvinue S, Gallant J E, Moore R D (15 1996) Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection, JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 11 (5), 455-9
• Gallant J E, Ko A H (1996) Cavitary pulmonary lesions in patients infected with human immunodeficiency virus, CLINICAL INFECTIOUS DISEASES, 22 (4), 671-82
• Maenza J R, Keruly J C, Moore R D, Chaisson R E, Merz W G, Gallant J E (1996) Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients, JOURNAL OF INFECTIOUS DISEASES, 173 (1), 219-25
• Maenza JR, Keruly JC, Moore RD, Chaisson RE, Gallant JE (1996) Risk factors for fluconazole-resistant candidiasis in HIV-infected patients, Journal of Infectious Diseases, 173, 219-25
• Godofsky EW, Gallant JE, Zurlo JJ, Shaw JC, Bergethon PR (1996) Primary care of the HIV-infected patient, Textbook of Primary Care Medicine, St. Louis, Mosby, 923-61 pages (bookchapter)
• Gallant J E, Moore R D, Keruly J, Richman D D, Chaisson R E (1995) Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine Zidovudine Epidemiology Study Group, JOURNAL OF INFECTIOUS DISEASES, 172 (2), 346-52
• Gallant J E, McAvinue S M, Moore R D, Bartlett J G, Stanton D L, Chaisson R E (1995) The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia, CHEST, 107 (4), 1018-23
• Gallant J E (1995) Infectious complications of HIV disease, EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 13 (1), 73-104
• Gallant JE, Moore RD, Keruly J, Richman DD, Chaisson RE (1995) Lack of association between acyclovir use and survival in patients with advanced HIV disease treated with zidovudine. The Zidovudine Epidemiology Study Group, Journal of Infectious Diseases, 172, 346-52
• Gallant JE, McAvinue SM, Moore RD, Bartlett JG, Stanton DL, Chaisson RE (1995) The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia, Chest, 107, 1018-23
• Gallant JE, Moore RD, Chaisson RE (1 1994) Prophylaxis for opportunistic infections in patients with HIV infection, Annals of Internal Medicine, 120 (11), 932-44
• Gallant J E, Moore R D, Richman D D, Keruly J, Chaisson R E (14 1994) Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine Zidovudine Epidemiology Study Group, ARCHIVES OF INTERNAL MEDICINE, 154 (5), 566-72
• Gallant JE, Moore RD, Chaisson RE. (1994) Prophylaxis for opportunistic infections in patients with HIV infection, Annals of Internal Medicine, 120, 932-44
• Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE (1994) Risk factors for Kaposi's sarcoma in patients with advanced HIV disease treated with zidovudine. The Zidovudine Epidemiology Study Group, Archives of Internal Medicine, 38, 1534-40
• Gallant JE, Chaisson RE (1994) Respiratory infections in HIV-infected persons, Respiratory Infections: A Scientific Basis for Management, Philadelphia, W.B. Saunders Co., 199-216 pages (bookchapter)
• Gallant J E, Eldred L J, Leslie J M, Chaisson R E, Quinn T C (1993) Impact of the 1993 revision of the CDC case definition on the performance of the WHO and PAHO clinical case definitions for AIDS letter, AIDS, 7 (10), 1396-7
• Chaisson R E, Stanton D L, Gallant J E, Rucker S, Bartlett J G, Moore R D (1993) Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting, AIDS, 7 (6), 857-62
• Gallant J E, Moore R D, Richman D D, Keruly J, Chaisson R E (1992) Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine The Zidovudine Epidemiology Study Group, JOURNAL OF INFECTIOUS DISEASES, 166 (6), 1223-7
• Gallant J E, Somani J, Chaisson R E, Stanton D, Smith M, Quinn T C (1992) Diagnostic accuracy of three clinical case definitions for advanced HIV disease, AIDS, 6 (3), 295-9
• Szych C M, Rotter S M, Gallant J E (1991) Papules and nodules in a patient with the acquired immunodeficiency syndrome and recurrent cryptococcal meningitis Bacillary angiomatosis or epithelioid angiomatosis, ARCHIVES OF DERMATOLOGY, 127 (12), 1832-3, 1835-6